Drug Profile
VRC-HIVADV052-00-VP
Alternative Names: HIV vaccine rAd5-Env-B VRC; rAd5 env B; rAd5 HIV vaccine VRC Env-B; rAd5-EnvB vaccine; VRC-rAd5 HIV vaccine Env-BLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator GenVec
- Developer GenVec; Vaccine Research Center
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 16 Jun 2017 GenVec has been acquired by Intrexon Corporation
- 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-1-infections(Prevention, In volunteers) in USA (IM)